II期临床研究-话题@MedSci

#II期临床研究#

109篇内容 | 2840人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1649958, encodeId=af841649958bd, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Lancet Oncol：舒尼替尼治疗化疗难治性胸腺瘤和胸腺癌---项开放的II期临床研究, objectType=article, longId=46140, objectId=3e594614037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e594614037, replyNumber=0, likeNumber=65, createdTime=2016-01-06, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e594614037, moduleTitle=Lancet Oncol：舒尼替尼治疗化疗难治性胸腺瘤和胸腺癌---项开放的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e594614037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649957, encodeId=5191164995eb7, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究, objectType=article, longId=43449, objectId=ff854344901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff854344901, replyNumber=0, likeNumber=70, createdTime=2015-01-27, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff854344901, moduleTitle=NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff854344901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649956, encodeId=2b571649956a2, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=默克雪兰诺启动抗PD-L1免疫疗法II期临床研究, objectType=article, longId=38553, objectId=67103855384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67103855384, replyNumber=0, likeNumber=63, createdTime=2015-02-18, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67103855384, moduleTitle=默克雪兰诺启动抗PD-L1免疫疗法II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67103855384)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649955, encodeId=a59d164995503, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）, objectType=article, longId=38150, objectId=2fcf38150b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fcf38150b2, replyNumber=0, likeNumber=53, createdTime=2014-09-29, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fcf38150b2, moduleTitle=COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fcf38150b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649954, encodeId=d98a1649954d1, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=阿斯利康开展司美替尼用于NSCLC的III期临床研究, objectType=article, longId=25791, objectId=ebe925e9168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebe925e9168, replyNumber=0, likeNumber=79, createdTime=2014-02-21, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebe925e9168, moduleTitle=阿斯利康开展司美替尼用于NSCLC的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebe925e9168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649953, encodeId=ac9c16499533a, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=昆泰在I、II、III期临床研究市场报告中被誉为**提供商, objectType=article, longId=22899, objectId=7a9e22899e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a9e22899e4, replyNumber=0, likeNumber=61, createdTime=2013-08-26, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a9e22899e4, moduleTitle=昆泰在I、II、III期临床研究市场报告中被誉为**提供商, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a9e22899e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649952, encodeId=50c5164995248, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=NEJM：Semagacestat用于老年性痴呆的III期临床研究失败, objectType=article, longId=22118, objectId=4568221184b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4568221184b, replyNumber=0, likeNumber=75, createdTime=2014-01-12, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4568221184b, moduleTitle=NEJM：Semagacestat用于老年性痴呆的III期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4568221184b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649951, encodeId=b234164995194, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=药品II期临床研究方案格式, objectType=article, longId=17497, objectId=50781e49742, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50781e49742, replyNumber=0, likeNumber=81, createdTime=2013-11-03, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50781e49742, moduleTitle=药品II期临床研究方案格式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50781e49742)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649947, encodeId=c00d164994ef6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=farletuzumab治疗卵巢癌将开始III期临床研究, objectType=article, longId=5402, objectId=d871540247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d871540247, replyNumber=0, likeNumber=67, createdTime=2012-09-14, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d871540247, moduleTitle=farletuzumab治疗卵巢癌将开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d871540247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649949, encodeId=524b164994925, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=慢性淋巴白血病用药GS-1101 开始III期临床研究, objectType=article, longId=5993, objectId=220059936c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=220059936c, replyNumber=0, likeNumber=77, createdTime=2012-07-14, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=220059936c, moduleTitle=慢性淋巴白血病用药GS-1101 开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=220059936c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649950, encodeId=d62616499508c, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益, objectType=article, longId=10558, objectId=8e311055832, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e311055832, replyNumber=0, likeNumber=66, createdTime=2013-05-21, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e311055832, moduleTitle=Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e311055832)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649948, encodeId=77501649948e9, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Idera公司着手银屑病用药IMO-3100II期临床研究, objectType=article, longId=5770, objectId=4b1a5e70ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b1a5e70ea, replyNumber=0, likeNumber=78, createdTime=2012-12-22, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b1a5e70ea, moduleTitle=Idera公司着手银屑病用药IMO-3100II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b1a5e70ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床研究

2020-05-29

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Lancet Oncol：舒尼替尼治疗化疗难治性胸腺瘤和胸腺癌---项开放的II期临床研究

2016-01-06

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究

2015-01-27

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

默克雪兰诺启动抗PD-L1免疫疗法II期临床研究

2015-02-18

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）

2014-09-29

仁医06 (审核中...)

前往app查看评论内容

#II期临床研究#

阿斯利康开展司美替尼用于NSCLC的III期临床研究

2014-02-21

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

昆泰在I、II、III期临床研究市场报告中被誉为**提供商

2013-08-26

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

NEJM：Semagacestat用于老年性痴呆的III期临床研究失败

2014-01-12

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

药品II期临床研究方案格式

2013-11-03

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

farletuzumab治疗卵巢癌将开始III期临床研究

2012-09-14

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

慢性淋巴白血病用药GS-1101 开始III期临床研究

2012-07-14

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益

2013-05-21

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Idera公司着手银屑病用药IMO-3100II期临床研究

2012-12-22

科室
- - 订阅+
  - 更多科室
工具
服务